Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Fernando Moreno Antón
- Target Recruit Count
- 237
- Registration Number
- NCT04109261
- Locations
- 🇪🇸
Fernando Moreno, Madrid, Spain
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT04075604
- Locations
- 🇺🇸
The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04060862
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇨🇦Hopital du Saint Sacrement, Quebec City, Quebec, Canada
🇺🇸Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 102
- Registration Number
- NCT03981614
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 141
- Registration Number
- NCT03969121
- Locations
- 🇯🇵
Saitama Cancer Center, Saitama, Japan
🇯🇵Toranomon Hospital, Tokyo, Japan
🇯🇵Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT03959891
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
UK Ibrance Patient Program (IPP) Study
- Conditions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT03921866
- Locations
- 🇬🇧
Royal Cornwall Hospital, Truro, Cornwall, United Kingdom
🇬🇧Guys and St Thomas' NHS Trust, London, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 17
- Registration Number
- NCT03900884
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 200
- Registration Number
- NCT03870919
- Locations
- 🇫🇷
ICM Val d'Aurelle, Montpellier, France
🇫🇷Hôpital Saint Louis APHP, Paris, France
🇫🇷Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.